| Cancer Prevention | NRG-CC008
A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers [SOROC] |
| All | GOG 136
Tissue Bank: Acquisition of Human Gynecologic Specimens to be used in Studying the Causes, Diagnosis, Prevention and Treatment of Cancer |
| Cervical | Iovance-C-145-04
A Phase 2 Study to Evaluate the Safety, Tolerability and Efficacy of Cell Transfer Therapy Using Autologous Tumor Infiltrating Lymphocytes (LN-145) followed by IL-2 in Patients with Recurrent and/or Metastatic Cervical Carcinoma
Keywords: Cervical cancer, recurrent , metastatic, LN-145, TILs |
| Cervical | ADVAXIS ADXS 001-004
Phase 1-2 Study of ADXS11-001 or MEDI4736 Alone or Combination In Previously Treated Locally Advanced or Metastatic Cervical or HPV+ Head & Neck Cancer
Keywords: Cervical, Recurrent, Metastatic, ADXS11-001, Randomized |
| Cervical | Anti PD-L1 Atezolizumab)
Immune Primer and Concurrently With Extended Field Chemoradiotherapy for Node Positive Locally Advanced Cervical Cancer
Keywords: Cervical Cancer, Atezolizumab, Cisplatin, Chemoradiotherapy, Node Positive, Anti PD-L1 |
| Cervical | GOG 263
Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk, Stage I/IIA, Cervical Cancer Treated with Initial Radical Hysterectomy and Pelvic Lymphadenectomy
Keywords: Stage I/IIA Cervical Cancer |
| Cervical | GOG 274
A Phase III Trial of Adjuvant Chemotherapy Following Chemoradiation as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: THE OUTBACK TRIAL
Keywords: Phase 3, Cervical Cancer, Chemotherapeutic Agent, Toxicity, Cognitive/Functional Effects, Psychosocial Effects of Cancer and Its Treatment, Radiation Toxicity, Sexuality and Reproductive Issues, The Outback Trial |
| Cervical | GOG 265
A Phase II Evaluation of ADXS11-001 in the Treatment of Persistent or Recurrent Squamous or Non-Squamous Cell Carcinoma of the Cervix
Keywords: Phase II, Cervical Cancer, Recurrent |
| Cervical | GOG 3023/Genmab GCT1015-04
A Single arm, Multicenter, International Trial of Tisotumab Vedotin (HuMax®-TF-ADC) in Previously Treated, Recurrent or Metastatic Cervical Cancer
Keywords: Recurrent Cervical Cancer, Metastatic Cervical Cancer, Squamous Cell, Adenocarcinoma, Adenosquamous Histology, Tisotumab Vedotin, Genmab |
| Cervical | ADXS001-02
A Phase 3 Study of ADXS11-001 Administered Following Chemoradiation as Adjuvant Treatment for High Risk Locally Advanced Cervical Cancer: AIM2CERV (Advaxis Immunotherapy to prevent Cervical recurrence)
Keywords: Cervical, ADXS11-001, Adjuvant, High risk, Locally Advanced, AIM2CERV, Phase 3 |
| Cervical | NRG-GY006
A Randomized Phase II Trial of Radiation Therapy and Cisplatin Alone or in Combination with Intravenous Triapine in Women with Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer
Keywords: Randomized, Phase II, Cisplatin, Stage II-IVA |
| Cervical or Pre-Cancer | GOG 207
A Randomized Double-Blind Phase II Trial of Celecoxib, A COX-2 Inhibitor, in the Treatment of Patients with Cervical Intraepithelial Neoplasia 2/3 or 3 (CIN 2/3 or 3) |
| Cervical or Pre-Cancer | GOG 219
A Phase III, Randomized Trial of Weekly Cisplatin and Radiation versus Cisplatin and Tirapazamine (IND# 46525) and Radiation in Stage IB2, IIA, IIB, IIIB and IVA Cervical Carcinoma Limited to the Pelvis |
| Cervical or Pre-Cancer | GOG 227E
Cervix: A Phase II Evaluation of Cetuximab (Erbitux®, C225, NSC# 714692) in the Treatment of Persistent or Recurrent Squamous or Non-Squamous Cell Carcinoma of the Cervix |
| Cervical or Pre-Cancer | GOG 240
A Randomized Phase III Trial of Cisplatin plus Paclitaxel with and without Bevacizumab versus the Non-Platinum Doublet, Topotecan plus Paclitaxel, with and without Bevacizumab, in Stage IVB, Recurrent or Persistent Carcinoma of the Cervix
Press Release
Keywords: Recurrent or Persistent Carcinoma of the Cervix |
| Endometrial | NRG-GY020
A Phase III Randomized Trial of Radiation +/- MK-3475 (Pembrolizumab) for Newly Diagnosed Early Stage High Intermediate Risk Mismatch Repair Deficient (dMMR) Endometrioid Endometrial Cancer
Keywords: Endometrial Neoplasms, Endometrioid Carcinoma, Adenocarcinoma, Glandular and Epithelial Neoplasms, Uterine Neoplasms, Female Genital Neoplasms, Urogenital Neoplasms, Ovarian Neoplasms, Pembrolizumab |
| Endometrial | T Regulatory Cells and DNA Methylation in Early Endometrial Cancer Before and After Treatment
Keywords: Endometrial |
| Endometrial | GOG 86P
A Three Arm Randomized Phase II Study of Paclitaxel/Carboplatin/Bevacizumab, Paclitaxel/\Ccarboplatin/Temsirolimus and Ixabepilone/Carboplatin/ Bevacizumab as Initial Therapy for Measurable Stage III or IVA,, Stage IVB, or Recurrent Endometrial Cancer |
| Endometrial | GOG 184
A Randomized Phase III Study of Tumor Volume Directed Pelvic Plus or Minus Para-Aortic Irradiation Followed by Cisplatin and Doxorubicin or Cisplatin, Doxorubicin and Paclitaxel for Advanced Endometrial Cancer |
| Endometrial | GOG 209
A Randomized Phase III Trial of Doxorubicin/ Cisplatin/ Paclitaxel/G-CSF versus Carboplatin/Paclitaxel in Patients with Stage III & IV or Recurrent Endometrial Cancer |
| Endometrial | GOG 249
A Phase III Trial of Pelvic Radiation Therapy Versus Vaginal Cuff Brachytherapy Followed by Paclitaxel/Carboplatin Chemotherapy in Patients with High Risk, Early Stage Endometrial Carcinoma
Keywords: Early Stage Endometrial Cancer, Brachytherapy, Radiation Therapy |
| Endometrial | GOG 258
A Randomized Phase III Trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel vs. Carboplatin and Paclitaxel for Optimally Debulked, Advanced Endometrial Carcinoma
Keywords: Advanced Endometrial Carcinoma |
| Endometrial | GOG-0286B
A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) Versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer
Keywords: Endometrial, GOG-0286B, Phase II/III, Recurrent, Stage III, Stage IVA, Stage IVB |
| Endometrial | GOG 286B
A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin Versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer
Keywords: Randomized, Phase II, Phase III, Chemotherapeutic, Stage III, Stage IVA, Stage IVb, Endometrial Cancer, Recurrent |
| Endometrial | GOG-3041-AZD9311C00001-DUO
A Randomised, Multicentre, Double-blind, Placebo-controlled, Phase III Study of First-line Carboplatin and Paclitaxel in Combination with Durvalumab, Followed by Maintenance Durvalumab with or without Olaparib in Patients with Newly Diagnosed Advanced or Recurrent Endometrial Cancer (DUO-E)
Keywords: Paclitaxel, Docetaxel, Bevacizumab, Carboplatin, Pembrolizumab, Olaparib |
| Endometrial | GOG LAP 2
A Phase III Clinical Trial of Laparoscopic Pelvic and Para-Aortic Node Sampling with Vaginal Hysterectomy and BSO versus Open Laparotomy with Pelvic and Para-Aortic Node Sampling and Abdominal Hysterectomy and BSO in Endometrial Adenocarcinoma, Clinical Stage I, IIA, Grade I, II, III |
| Endometrial | Ergomed/AEZS-108-050
Randomized Controlled Study Comparing AEZS-108 with Doxorubicin as Second Line Therapy for Locally Advanced, Recurrent or Metastatic Endometrial Cancer
Keywords: Endometrial, Second Line Therapy, Advanced Endometrial Cancer, Recurrent Endometrial Cancer, Metastatic Endometrial Cancer, Doxorubicin, Phase 3 |
| Endometrial | Genentech
Maggie: A Multicenter, Single-Arm, Open-Label, Phase II Study of GDC-0980 For the Treatment of Recurrent or Persistent Endometrial Carcinoma |
| Epithelial Ovarian Cancer (EOC) | GOG-3036-MERCK-7339-001
A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First- Line Treatment of BRCA non-mutated Advanced Epithelial Ovarian Cancer (EOC) |
| Epithelial Ovarian, Peritoneal, Fallopian Tube | IMMUNOGEN-IMGN853-0417-SORAYA
A Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
Keywords: Platinum resistant, Folate-receptor alpha expression, Phase 3, Antibody-drug conjugate, mirvetuximab soravtansine, IMGN853, Epithelial Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer, MIRV, FRα |
| Epithelial Ovarian, Fallopian Tube or Primary Peritoneal | CELSION-201-17-201
Phase I-II Study Evaluating the Dosing, Safety, Efficacy and Biological Activity of Intraperitoneal GEN-1 (IL-12 Plasmid Formulated with PEG-PEI-Cholesterol Lipopolymer) Administered in Combination with Neoadjuvant Chemotherapy (NACT) in Patients Newly Diagnosed with Advanced Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Keywords: Ovarian Neoplasms, Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Female Genital Neoplasms |
| VIN 3/ HPV, Pre-cancer, HPV | INOVIO- HPV-201
A Phase 2, Randomized, Open Label, Efficacy Study of VGX-3100 Delivered Intramuscularly Followed by Electroporation with CELLECTRA® 2000 Alone or in Combination With Imiquimod, for the Treatment of HPV-16 and/or HPV-18 Related High Grade Squamous Intraepithelial Lesion (HSIL) of the Vulva
Keywords: Pre-Cancer, Vulvar, VIN, HPV |
| Ovarian and Endometrial | Leap DEK-DKK1-P204
A Phase 2 Study Evaluating the Efficacy and Safety of DKN-01 as a Monotherapy or in Combination with Paclitaxel in Patients With Recurrent Epithelial Endometrial or Epithelial Ovarian Cancer
Keywords: Epithelial Ovarian Cancer, Epithelial Endometrial Cancer, High-Grade Serous, Low-Grade Serous, Mucinous, Endometrioid, Clear Cell, Undifferentiated or Unclassified, DKN-01, Recurrent |
| Ovarian and Endometrial | Tesaro TSR-042 4010-01-001
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an anti-PD1 Monoclonal Antibody in Patients with Advance Solid tumors
Keywords: Ovarian, Endometrial, Platinum-Resistant, Tesaro, TSR-042, Advanced, 4010-01-001, Phase 1, Anti-PD1 Monoclonal Antibody, Solid Tumors |
| Ovarian | NRG-GY007
A Phase I/II STUDY OF Ruxolitinib With Front-Line Neoadjuvant And Post-Surgical Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Keywords: Ruxolitinib, Neoadjuvant, Epithelial Ovarian |
| Ovarian | NRG -GY021
The study is intended to determine whether olaparib plus tremelimumab has adequate safety in the study population and to compare the progression-free survival (PFS) duration of olaparib monotherapy versus olaparib plus tremelimumab in women with recurrent, platinum sensitive ovarian, primary peritoneal, or fallopian tube cancer.
Keywords: Ovarian, Recurrent Ovarian Cancer, Platinum-Sensitive Ovarian Cancer, Olaparib, PARP inhibitor, Tremelimumab, CTLA4 immune checkpoint inhibitor, Immunotherapy, high-grade serous, high-grade endometrioid, BRCA1 or BRCA2 mutation |
| Ovarian | CORT125134-552 (Corcept)
A Phase 2, Randomized, Open-label, 3-arm Study of Relacorilant in Combination with Nab-Paclitaxel for Patients with Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Keywords: Recurrent Ovarian Cancer, Platinum Resistant Ovarian Cancer, Ovarian, Fallopian Tube, Primary Peritoneal, Nab-Paclitaxel, Relacorilant, Corcept, CORT125134-552 |
| Ovarian | GOG 3005 A Phase 3 Placebo-
Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (PRO00024744)
Keywords: Ovarian, Primary, Maintenance, Untreated, PARP Inhibitor, PARP, Veliparib, Serous |
| Ovarian | GOG 182
A Phase III Randomized Trial of Paclitaxel and Carboplatin versus Triplet or Sequential Doublet Combinations in Patients with Epithelial Ovarian or Primary Peritoneal Carcinoma |
| Ovarian | GOG 186H
A Randomized Phase II Evaluation of Weekly Paclitaxel (NSC# 673089) versus Weekly Paclitaxel with Oncolytic Reovirus (Reolysis NSC # 729968, BB-IND # 13370) in the Treatment of Recurrent or Persistent Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Keywords: Recurrent, Fallopian tube, Ovarian Epithelial, Primary Peritoneal, Viral Therapy, Chemotherapy, Phase II |
| Ovarian | GOG 212
A Randomized Phase III Trial of Maintenance Chemotherapy Comparing 12 Monthly Cycles of Single Agent Paclitaxel or Xyotax (CT-2103) (IND# 70177), Versus No Treatment Until Documented Relapse in Women With Advanced Ovarian or Primary Peritoneal or Fallopian Tube Cancer Who Achieve a Complete Clinical Response to Primary Platinum/Taxane Chemotherapy
Keywords: Relapse in Women with Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer |
| Ovarian | GOG 213
A phase III randomized controlled clinical trial of carboplatin and paclitaxel alone or in combination with Bevacizumab, followed by Bevacizumab and secondary cytoreduction surgery in platinum-sensitive, recurrent ovarian, fallopian tube and peritoneal primary cancer
Keywords: Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer |
| Ovarian | GOG 218
Ovarian and Primary Peritoneal: A Phase III Trial of Carboplatin and Paclitaxel plus Placebo versus Carboplatin and Paclitaxel plus Concurrent Bevacizumab (NSC #704865, IND# 7921) Followed by Placebo versus Carboplatin and Paclitaxel plus Concurrent and Extended Bevacizumab in Women with Newly Diagnosed, Previously Untreated, Stage III or IV, Epithelial Ovarian or Primary Peritoneal or Fallopian Tube Cancer |
| Ovarian | GOG 225
Can Diet and Exercise Modulate Ovarian, Fallopian Tube or Peritoneal Cancer Progression-Free Survival?
Keywords: Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer, Weight Change, Healthy Lifestyle |
| Ovarian | GOG 235
A Prospective, Longitudinal Study of YKL-40 in Patients with FIGO Stage III or IV Invasive Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Undergoing Primary Chemotherapy
Keywords: Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer, Tumor Marker |
| Ovarian | GOG 241
A GCIG Intergroup Multicenter Phase III Trial of Open Label Carboplatin and Paclitaxel +/- NCI-Supplied Agent: Bevacizumab Compared with Oxaliplatin and Capecitabine +/- Bevacizumab as First Line Chemotherapy in Patients with Mucinous Epithelial Ovarian or Fallopian Tube Cancer (MEOC)
Keywords: Ovarian Mucinous Cystadenocarcinoma, Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer, Oxaliplatin |
| Ovarian | GOG 244
The Lymphedema and Gynecologic Cancer (LEG) Study: Incidence, Risk Factors, and Impact in Newly Diagnosed Patients
Keywords: Cervical Cancer, Endometrial Cancer, Vulvar Cancer, Lymphedema, Quality of Life |
| Ovarian | GOG 252
Ovarian: A Phase III Clinical Trial of Bevacizumab with IV versus IP Chemotherapy in Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma NCI-Supplied Agents(s): Bevacizumab (NSC #704865, IND# 7921) |
| Ovarian | GOG 267
Quality of Life and Care Needs in Patients With Persistent or Recurrent Platinum-Resistant Ovarian, Fallopian Tube, and Peritoneal Cancer
Keywords: Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer, Quality of Life |
| Ovarian | GOG 268
A Phase II Evaluation of Temsirolimus in Combination with Carboplatin and Paclitaxel followed by Temsirolimus Consolidation as First-line Therapy in the Treatment of Clear Cell Carcinoma of the Ovary
Keywords: Clear Cell Carcinoma of the Ovary |
| Ovarian | GOG 255
A Phase II Randomized, Double-Blind Trial of a Polyvalent Vaccine-KLH Conjugate + OPT-821 Versus OPT-821 in Patients with Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer who are in Second or Third Complete Remission
Keywords: Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer, Vaccine |
| Ovarian | GOG 261
A Randomized Phase III trial of Paclitaxel plus Carboplatin versus Ifosfamide Plus Paclitaxel in Chemotherapy-Naive Patients with Newly Diagnosed Stage I-IV, Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus or Ovary
Keywords: Recurrent or Persistent Ovarian, Sarcoma |
| Ovarian | GOG 262
A Randomized Phase III Trila of every 3 weeks Paclitaxel Versus Dose Dense Weekly Paclitaxel in Combination with Caboplatin with or without Concurrent and Consolidation Bevacizumab in the Treatment of Primary Stage III or IV Epithelial Ovarian, Peritoneal or Fallopian Tube Cancer
Keywords: Stage III or IV Epithelial Ovarian, Peritoneal or Fallopian Tube Cancer |
| Ovarian | GOG 272
Pilot Study of Standard Therapy for Prevention of Nausea Associated with First Line Post-operative Intraperitoneal Chemotherapy
Keywords: Stage II, III or IV Ovarian, Fallopian Tube, or Primary Peritoneal |
| Ovarian | GOG 273
Chemotherapy Toxicity in Elderly Women with Ovarian, Primary Peritoneal, or Fallopian Tube Cancer |
| Ovarian | GOG 281
A randomized phase II/III study to assess the efficacy of trametinib (GSK 1120212) in patients with recurrent or progressive low-grade serous ovarian cancer or peritoneal cancer
Keywords: Low-Grade, Low-Grade Serous, Recurrent |
| Ovarian | GOG 3001
A Phase 3 Randomized, Double-Blind, Placebo-Controlled, GOG 3001-Multi-Center Study of AMG 386 With Paclitaxel and Carboplatin as First-line Treatment of Subjects With FIGO Stage III-IV Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancers (Amgen Protocl #2010129)
Keywords: Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer |
| Ovarian | GOG 3003
A Randomized, Double-Blind, Placebo-Controlled Phase II Study of VTX-2337 (IND#78,416) in Combination with Pegylated Liposomal Doxorubicin (PLD) in Patients with Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Keywords: Recurrent, Persistent, Ovarian, Fallopian Tube, Primary Peritoneal |
| Ovarian | GOG 3004
A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in Patients with BRCA Mutated Advanced (FIGO Stage III-IV) Ovarian Cancer following First Line Platinum Based Chemotherapy
Keywords:Olaparib, Newly Diagnosed, Advanced Ovarian Cancer, FIGO Stage III-IV, BRCA Mutation |
| Ovarian | GOG 3005 A Phase 3 Placebo-
Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (PRO00024744)
Keywords: Ovarian, Primary, Maintenance, Untreated, PARP Inhibitor, PARP, Veliparib, Serous |
| Ovarian | GOG-3018-VBL-VB-111-701
The OVAL Study: A Randomized, Controlled, Double-Arm,Double-Blind, Multi-Center Study of Ofranergene Obadenovec (VB-111) Combined with Paclitaxel vs. Paclitaxel Combined with Placebo for theTreatment of Recurrent Platinum-Resistant Ovarian Cancer
Keywords: Recurrent Ovarian cancer, Platinum resistant ovarian cancer, Ovarian cancer, Ovarian carcinoma, Epithelial ovarian cancer, paclitaxel |
| Ovarian | GOG 3013
A Phase 3, Multicenter, Randomized, Open-label Study Of Avelumab (MSB0010718C) Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum-resistant/Refractory Ovarian Cancer
Keywords: Ovarian, Platinum Resistant, Platinum Refractory, Avelumab, Randomized |
| Ovarian | GOG 3048
Mersana First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b
Keywords: Platinum-Resistant, Mersana Therapeutics, XMT-1536 (upifitamab rilsodotin), Antibody-Drug Conjugate (ADC), Early Phase, High Grade Serous, First in Human, Measurable Disease |
| Ovarian | GOG-3059
A Phase 3, Randomized, Double-Blind, Adaptive, Placebo/Paclitaxel-Controlled Study of AVB-S6-500 in Combination with Paclitaxel in Patients with Platinum-Resistant Recurrent Ovarian Cancer
Keywords: Ovarian Neoplasms, Carcinoma, Ovarian Epithelial |
| Ovarian | GOG 9927
A Phase I Trial of Pegylated Liposomal Doxorubicin (PLD), Carboplatin and NCI Supplied Veliparib (ABT-888) and NCI Supplied Bevacizumab in Recurrent Platinum Sensitive Ovarian, Primary Peritoneal and Fallopian Tube Cancer
Keywords: Recurrent Ovarian, Primary Peritoneal, Fallopian Tube |
| Ovarian | GOG 9928
A Phase I Study of Intraperitoneal Egen-001 Administered in Combination with Pegylated Liposomal-Doxorubicin in Patients with Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Keywords: Recurrent, Persistent, Epithelial Ovarian, Fallopian Tube, Primary Peritoneal |
| Ovarian | GOG 3011/Immunogen
Forward 1: A Randomized, Open Label Phase 3 Study to Evaluate the Safety and Efficacy of Mirvetuximab Soravtansine (IMGN853) versus Investigator’s Choice of Chemotherapy in Women with Folate Receptor α–positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer Or Fallopian Tube Cancer
Keywords: Forward 1, Phase 3, Mirvetuximab Soravtansine, IMGN853, Immunogen, Folate receptor α-positive, Epithelial, Ovarian, Primary Peritoneal, Fallopian tube |
| Ovarian | GOG 3012 - TESARO
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients with HRD-Positive Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy
Keywords: HRD-positive, advanced Ovarian, Niraparib, Randomized, Double-blind |
| Ovarian | NRG-GY001
A Phase II Trial of Cabozantinib (XL-184) (NSC #761968) in Women With Recurrent, Clear Cell Carcinoma of the Ovary, Fallopian Tube, or Peritoneum
Keywords: Ovarian, Recurrent, Cabozantinib, Clear cell |
| Ovarian | Amgen 386 Study 20090508
A Phase 3, Randomized, Double-blind Trial of Paclitaxel Plus AMG 386 or Placebo in Women with Recurrent Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancers Following a Prior Platinum-Containing Regimen |
| Ovarian | Celsion Gen-1 Phase I Neoadjuvant Ovarian
A Phase I Study of the Safety and Biological Activity of Intraperitoneal GEN-1 (IL-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered In Combination With Standard Neoadjuvant Chemotherapy in Patients Newly Diagnosed With Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Keywords: Phase 1, Ovarian, Neoadjuvant |
| Ovarian | GYN49 AZD1775
A Multicenter Randomized Phase II Study of AZD1775 plus Chemotherapy versus Chemotherapy Alone in Patients with Platinum-Resistant TP53-Mutated Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (GYN 49)
Keywords: Platinum Resistant, TP53, Recurrent, Phase II |
| Ovarian | MERCK
A Study of MK-1775 in Combination with Paclitaxel and Carboplatin versus Paclitaxel and Carboplatin Alone in Adult Patients with Platinum Sensitive p53 Mutant Ovarian Cancer |
| Ovarian | MERCK 3475-100
A Phase II, Open-label, Single-arm, Multicenter Study to Evaluate Efficacy and Safety of Pembrolizumab Monotherapy in Subjects with Advanced Recurrent Ovarian Cancer (KEYNOTE -100)
Keywords: Ovarian, Keynote, Pembrolizumab, Recurrent |
| Ovarian | NRG-CC002
Pre-operative Assessment and Post-Operative Outcomes of Elderly Women With Gynecologic Cancers
Keywords: QOL, Quality of Life, Surgery, 70+ |
| Ovarian | NRG-GY004
A Phase III study comparing single-agent olaparib or the combination of cediranib and olaparib to standard platinum-based chemotherapy in women with recurrent platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer
Keywords: Phase III, Olaparib, Cediranib, Platinum-Based, Ovarian |
| Ovarian | NRG-GY005
A Randomized Phase II/III study of the combination of Cediranib and Olaparib compared to Cediranib or Olaparib alone, or Standard of care chemotherapy in women with recurrent platinum-resistant or -refractory ovarian, fallopian tube, or primary peritoneal cancer (COCOS)
Keywords: Randomized, Cediranib, Olaparib, Ovarian, Platinum Resistant |
| Ovarian | Acerta ACE-ST-208
A Phase 2 Proof-of-Concept Study of ACP-196 Alone and in Combination with Pembrolizumab in Subjects with Recurrent Ovarian Cancer (PRO 25546) is now open to patient accrual.
Keywords: Ovarian Cancer, Phase 2, Recurrent, Pembrolizumab, ACP-196 |
| Ovarian | Janssen R&D Protocol ET743-OVC-3006
A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced Relapsed Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer
Keywords: Randomized, Open Label, Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer, Relapsed, Phase 3, Recurrent Ovarian Cancer, Doxil, Yondelis, BRCA, Platinum Sensitive, Third Line |
| Ovarian | AstraZeneca-Light Study D0816L00003
This is a non-randomized, open-label study to assess olaparib tablets as a treatment for subjects with different homologous recombination deficiency (HRD) tumor status and with platinum-sensitive, relapsed, high-grade serous or high-grade endometrioid ovarian cancer. Subjects should have received at least 1 prior line of platinum-based chemotherapy
Keywords: Ovarian, Parp, Olaparib, Light Study, Recurrent, Platinum Sensitive, High Grade, Endometriod, Serous |
| Ovarian or Pre-cancer | GOG 214
A Phase II Double Blind Randomized Trial Evaluating the Biologic Effect OF Levonorgestrel on the Ovarian Epithelium in Women at High Risk for Ovarian Cancer
Keywords: High risk for Ovarian, Prevention |
| Ovarian | SOLO3
A Phase III, Open Label, Randomised, Controlled, Multi-centre Study to Assess the Efficacy and Safety of Olaparib Monotherapy Versus Physician's Choice Single Agent Chemotherapy in the Treatment of Platinum Sensitive Relapsed Ovarian Cancer in Patients Carrying Germline BRCA1/2 Mutations
Keywords: BRCA1/2, Olaparib, Recurrent, Ovarian |
| Ovarian | The OVAL Study
A Randomized, Controlled, Double-Arm, Double Blind, Multi-Center Study of Ofranergene Obadenovec (VB-111) Combined with Paclitaxel vs. Paclitaxel Combined with Placebo for the Treatment of Recurrent Platinum-Resistant Ovarian Cancer
Other Study Identifiers: VB-111-701, GOG-3018
Keywords: Recurrent Ovarian Cancer, Platinum Resistant Ovarian Cancer, Ovarian, Ovarian Carcinoma, Epithelial Ovarian Cancer, Paclitaxel, VB-111, GOG-3018 |
| Ovarian | GOG-3020 / ENGOT-ov45/NCRI/ATHENA
This is a Phase 3, randomized, multinational, double-blind, dual placebo-controlled, 4-arm study evaluating rucaparib and nivolumab as maintenance treatment following response to front-line treatment in newly diagnosed ovarian cancer patients.
Keywords: Ovarian, Parp, Rucaparib, ATHENA y, Nivolumab, Maintenance, primary therapy, Front-Line Platinum-Based |
| Ovarian | IIT-Uyar Merck 3475-250
Phase II Open Label Nonrandomized Trial of the Anti PD 1 Therapy Pembrolizumab With First Line Platinum Based Chemotherapy Followed by 12 Months Pembrolizumab Monotherapy for Patients With Stage III/IV Epithelial Ovarian Cancer
Keywords: Suboptimal Cytoreduced, Ovarian, Pembrolizumab, First Line, Epithelial, Nonrandomized |
| Ovarian | HOFFMANN-LAROCHE-YO40482
A Phase Ib Study of Cobimetinib Administered In Combination with Niraparib, with or without Atezolizumab, to Patients with Advanced Platinum-Sensitive Ovarian Cancer
Keywords: Ovarian Neoplasms, Ovarian Epithelial Carcinoma, Endocrine Gland Neoplasms, Female Genital Neoplasms, Urogenital Neoplasms, Glandular and Epithelial Neoplasms |
| Ovarian, primary peritoneal, or fallopian tube cancer | NRG-GY023
A Randomized Phase II Trial of Triplet Therapy (A PD-L1 Inhibitor Durvalumab (MEDI4736) in Combination with Olaparib and Cediranib) Compared to Olaparib and Cediranib or Durvalumab (MEDI4736) and Cediranib or Standard of Care Chemotherapy in Women with Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Primary Peritoneal or Fallopian Cancer Who Have Received Prior Bevacizumab
Keywords: Durvalumab, Olaparib, or Cediranib, Recurrent Platinum Resistant, MEDI4736, Parp Inhibitor, Monoclonal Antibodies, VEGF, High Grade Serous, Grade 3 Endometrioid or Clear Cell Carcinoma, BRCA1 or BRCA2 Mutation |
| Recurrent Clear Cell Ovarian Cancer | NRG-GY016
A Phase II Study of MK-3475 (Pembrolizumab) (NSC #776864) + Epacadostat (NSC #766086) in Recurrent Clear Cell Carcinoma of the Ovary. (Single Arm Study)
Keywords: Ovarian, Clear Cell, Recurrent Clear Cell, Pembrolizumab, MK-3475 , Epacadostat , Immunotherapy, Phase 2, Recurrent, Persistent Disease, Monoclonal Antibodies, PDL-1, Measurable Disease |
| Uterine | GOG 277
A Phase III Randomized Trial of Gemcitabine Plus Docetaxel Followed by Doxorubicin Versus Observation for Uterus-Limited, High-Grade Uterine Leiomyosarcoma
Keywords: Uterine, Sarcoma, Leiomyosarcoma. |
| Uterine Serous Carcinoma | ERGOMED-ZN-C3-004
A Phase 2 Open-Label, Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Adult Women with Recurrent or Persistent Uterine Serous Carcinoma
Keywords: Uterine Serous Carcinoma, Cystadenocarcinoma, Serous, Neoplasms |
NRG is a non-profit organization with the purpose of promoting excellence in the quality and integrity of clinical and basic scientific research in the field of Gynecologic malignancies. The Group is committed to maintaining the highest standards in clinical trials development, execution, analysis and distribution of results. Continuous evaluation of our processes is utilized in order to constantly improve the quality of patient care.
The GOG Foundation is a nonprofit organization dedicated to transforming the standard of care in gynecologic oncology, conducting clinical and translational research that positively impacts patients through the prevention and treatment of gynecologic malignancies, including cancers that arise from the ovaries, uterus, cervix, vagina, and vulva.